glp-1/gip/glucagon triple agonist LY3437943, a novel glucagon, GIP, and GLP-1 receptor for glycemic control and weight loss: From discovery to clinical proof of concept Possible mechanisms of the interaction

PLoS ONE, 10 (6), e0130040

In research models, this mechanism has been studied in the context of photoprotection in UV-sensitive conditions particularly erythropoietic protoporphyria (EPP), where clinical development of afamelanotide as a subcutaneous implant has resulted in regulatory approval in Europe and the United States

GHRP-6 strongly stimulates appetite, while GHRP-2 and GHRP-6 can also raise cortisol and prolactin levels

MICC works best when paired with healthy eating, regular exercise, and follow-up visits with your healthcare provider

Improvements are typically discussed over days to weeks rather than hours